No internet connection — showing the saved version of the page.

Kala Pharmaceutic…

USUSD
← to the screener
US:KALALSE:0JQ2

Kala Pharmaceuticals Inc (LSE:0JQ2) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 2. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
kalarx.com
Investor relations
kalarx.com/investors/
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Headquarters
Waltham, United States
CEO
Avi Minkowitz
Employees
6
Founded
2009
Shares outstanding
19.34 M as of 2026-08-14
Free float
19.34 M
Market cap
5.68 M USD
Insiders
1.24%
Institutions
4.07%
Industry (SIC)
Pharmaceutical Preparations
FCF
—
Debt
26.9 M USD
Earnings and FCF — for the 12 months to 30.06.2026 (the company's latest report).
NAV
0.47 USD · P/NAV 1.10
Balance sheet date30.06.2026
Assets10.6 M USD
− Liabilities1.54 M USD
= NAV (equity of the company's shareholders)9.04 M USD
= Tangible NAV9.04 M USD
Shares19 339 786
NAV per share0.47 USD
Tangible NAV per share0.47 USD
Share price (0JQ2)0.5145 USD
P/NAV1.10
NAV history
Balance sheet dateNAVNAV per share
30.06.20269.04 M USD0.47 USD
31.03.202610.8 M USD0.58 USD
31.12.20257.00 M USD12.56 USD
30.09.2025−8.67 M USD−1.17 USD
30.06.2025−3.21 M USD−0.48 USD
31.03.20255.71 M USD0.88 USD
31.12.202412.3 M USD2.02 USD
30.09.20246.86 M USD1.49 USD
Description

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
US USA StocksKALA primaryUSD0.1899 -1.20%common stock
LSE London Stock Exchange0JQ2 IOBUSD0.5145 +0.00%common stock

Price for 3 months

up day down dayHover / tap a day — open, close, high and low prices

Top holders

HolderStakeSharesReport date
Vanguard Capital Managem…1.14%220 6232026-06-30
VANGUARD INDEX FUNDS-Van…1.14%220 6232026-06-30
Geode Capital Management…0.75%145 1522026-06-30
IWICKI MARK T. (Director…≈0.54%103 5402025-10-23
Vanguard Fiduciary Trust…0.52%101 3962026-06-30
Fidelity Concord Street…0.5%96 4922026-07-31
State Street Corporation0.46%88 5702026-06-30
Blackrock Inc.0.37%71 5422026-06-30
Northern Trust Corporati…0.22%41 6062026-06-30
KHARABI DARIUS (Officer)≈0.22%41 7602025-10-22
BRAZZELL ROMULUS KIM (Of…≈0.19%35 9522025-10-22
BAZEMORE TODD M (Directo…≈0.19%35 9332025-10-22
REUMUTH MARY (Chief Fina…≈0.15%28 9062025-10-23
Fidelity Concord Street…0.1%19 1972026-07-31
Fidelity Concord Street…0.09%17 3972026-07-31
KOVEN ANDREW IAN (Direct…≈0.09%16 9722025-06-13
ROSEN HOWARD B (Director…≈0.09%16 5022025-06-13
Fidelity Concord Street…0.07%12 8322026-07-31
PERRY GREGORY D (Directo…≈0.07%13 3442025-06-13
Qube Research & Technolo…0.06%11 0732026-06-30
Goldman Sachs Group Inc0.06%10 9212026-06-30
MYERS CHARLES DANIEL (Di…≈0.05%10 3742025-06-13
UBS Group AG0.05%9 0572026-06-30
Tower Research Capital L…0%6162026-06-30
John Hancock Variable In…0%3552026-06-30
BAKER BROS ADVISORS, L.P…——2025-10-01